Please ensure Javascript is enabled for purposes of website accessibility
Contact us Contact Us
EN
Home > Products > Assay Kits > ADA Assay Kits

Screen for anti-drug antibodies (ADA) with our 330+ immunogenicity assay kits. Designed in bridging ELISA format — the industry-standard approach for detecting ADA against therapeutic antibodies. Each kit includes matched drug-coated plates, detection reagents, and positive control antibodies for reliable immunogenicity assessment in preclinical and clinical sample analysis. All products are designated Research Use Only (RUO) — not intended for diagnostic or therapeutic procedures. RUO

Why Researchers Choose abinScience

Bridging ELISA Format Industry-standard assay architecture: drug-coated capture → ADA binding → drug-labeled detection. Detects all ADA isotypes in a single assay.
Matched Reagent Systems Each kit pairs with our anti-idiotype antibodies (positive controls) and research biosimilar antibodies (calibrators) — enabling complete assay validation.
Broad Drug Coverage ADA kits available for adalimumab, trastuzumab, pembrolizumab, nivolumab, rituximab, bevacizumab, infliximab, and 100+ other approved or pipeline therapeutics.
Translational Ready Validated across serum and plasma matrices from human, cynomolgus monkey, mouse, and rat — supporting preclinical-to-clinical immunogenicity programs.
Options+
Options
Confirm
  • Product types
    0 selected
    Assay Kit (338)
  • Target
    0 selected
    Durvalumab (3)
    A29L (4)
    Elezanumab (1)
    Spike glycoprotein (10)
    Secukinumab (2)
    Ustekinumab (3)
    Natalizumab (2)
    Rituximab (1)
    Mirzotamab (1)
    Gremubamab (1)
    Glycoprotein G (2)
    Nesvacumab (1)
    Milatuzumab (1)
    Befovacimab (1)
    Edrecolomab (1)
    Gevokizumab (1)
    Sibrotuzumab (1)
    Teprotumumab (1)
    Mirvetuximab (1)
    Panitumumab (3)
    Codrituzumab (1)
    Glofitamab (1)
    Ieramilimab (1)
    Benufutamab (1)
    Meplazumab (1)
    Zanolimumab (1)
    Lacnotuzumab (1)
    Vibecotamab (1)
    Rosopatamab (2)
    Pacmilimab (1)
    F/Fusion glycoprotein F0 (3)
    Spike Protein (Trimer) (2)
    CD20/MS4A1 (3)
    Foravirumab (1)
    RBD (Omicron/BA.5) (3)
    Mirikizumab (2)
    Omburtamab (1)
    M1R (4)
    Oleclumab (1)
    Vanucizumab (1)
    CD79B (2)
    Concizumab (1)
    Letolizumab (1)
    Bevacizumab (3)
    Dupilumab (3)
    Serclutamab (1)
    Clazakizumab (1)
    Ibritumomab (1)
    Conatumumab (1)
    Balstilimab (1)
    Olaratumab (1)
    Certolizumab (2)
    Tarextumab (1)
    Cabiralizumab (1)
    Tisotumab (1)
    Exenatide acetate (2)
    Guselkumab (3)
    Enfortumab (1)
    NP/Nucleocapsid (3)
    Mazdutide (1)
    Tibulizumab (1)
    Rafivirumab (1)
    dsDNA (1)
    Sotrovimab (1)
    Disitamab (1)
    Afasevikumab (1)
    Marstacimab (1)
    Rolinsatamab (1)
    Basiliximab (1)
    Amatuximab (1)
    Apamistamab (1)
    Brolucizumab (1)
    Astegolimab (1)
    Olokizumab (1)
    Mosunetuzumab (1)
    Mavezelimab (1)
    Drozitumab (1)
    Alacizumab (1)
    Eldelumab (1)
    Cetrelimab (1)
    Sacituzumab (1)
    Tovetumab (1)
    Emactuzumab (1)
    H3L (2)
    Nirsevimab (1)
    Etanercept (1)
    Vunakizumab (1)
    Glycoprotein (4)
    Dilpacimab (1)
    Casirivimab (1)
    Frovocimab (1)
    Urelumab (1)
    Imalumab (1)
    Zampilimab (1)
    Lupartumab (1)
    Ivuxolimab (1)
    Pertuzumab (3)
    Bimekizumab (1)
    Itolizumab (1)
    Camidanlumab (1)
    Anetumab (1)
    Ranibizumab (3)
    Iscalimab (1)
    Tesidolumab (1)
    Sirukumab (1)
    Ocaratuzumab (1)
    Favezelimab (1)
    Lexatumumab (1)
    Ramucirumab (1)
    Nivolumab (3)
    Bimagrumab (1)
    Golimumab (3)
    Lodelcizumab (1)
    E8L (4)
    Retatrutide (1)
    Palivizumab (3)
    Elotuzumab (1)
    Ianalumab (1)
    Tosatoxumab (1)
    Semaglutide (1)
    Navicixizumab (1)
    Imdevimab (1)
    Omalizumab (2)
    Utomilumab (1)
    Cixutumumab (1)
    Pogalizumab (1)
    Trastuzumab (2)
    Ixekizumab (1)
    Obinutuzumab (2)
    Anifrolumab (1)
    Daclizumab (1)
    Emibetuzumab (1)
    Varisacumab (1)
    Belantamab (1)
    Ziltivekimab (1)
    Tigatuzumab (1)
    Lenzilumab (1)
    Pembrolizumab (3)
    Semorinemab (1)
    Ipilimumab (2)
    A35R (4)
    β-D-Glucan (1)
    Suptavumab (1)
    Evolocumab (1)
    Romiplostim (1)
    Tiragolumab (2)
    GP/Envelope glycoprotein (3)
    Tremelimumab (1)
    Daratumumab (3)
    Infliximab (2)
    Dalotuzumab (1)
    Andecaliximab (1)
    Vofatamab (1)
    Depatuxizumab (1)
    Tavolimab (1)
    Zanidatamab (1)
    Afutuzumab (1)
    Cusatuzumab (1)
    Ontamalimab (1)
    Varlilumab (1)
    Tanezumab (1)
    Teclistamab (1)
    Carlumab (1)
    Indatuximab (1)
    Ascrinvacumab (1)
    Namilumab (1)
    Sintilimab (1)
    Tilavonemab (1)
    Tezepelumab (1)
    RBD (4)
    Alirocumab (1)
    Blosozumab (1)
    Eculizumab (3)
    Obiltoxaximab (1)
    Tirzepatide (1)
    Atezolizumab (3)
    Denosumab (3)
    Zagotenemab (1)
    Zalifrelimab (1)
    Magrolimab (1)
    Figitumumab (1)
    Losatuxizumab (1)
    Lirilumab (1)
    Icrucumab (1)
    Vorsetuzumab (1)
    Ibalizumab (1)
    Tocilizumab (3)
    Crizanlizumab (1)
    Cergutuzumab (1)
    Otilimab (1)
    Tislelizumab (1)
    Cetuximab (3)
    RBD (Delta) (2)
    Siltuximab (3)
    Remtolumab (1)
    Suvizumab (1)
    Romosozumab (1)
    Sarilumab (2)
    Enoblituzumab (1)
    Avelumab (3)
    Toripalimab (1)
    Ifabotuzumab (1)
    Canakinumab (1)
    Ganitumab (1)
    Farletuzumab (1)
    Oxelumab (1)
    Necitumumab (1)
    Zenocutuzumab (1)
    Epcoritamab (1)
    Tregalizumab (1)
    Glembatumumab (1)
    Inclacumab (1)
    Talacotuzumab (1)
    Adalimumab (3)
    Pasotuxizumab (1)
    Labetuzumab (1)
    Lorvotuzumab (1)
    Lintuzumab (1)
    Faricimab (1)
    Cinpanemab (1)
  • Applications
    0 selected
    ELISA (338)

Quick access

Contact Us

  • +86-27-65523339

  • info@abinscience.com

  • Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China

  • linkedin
  • Ins
  • youtube
  • youtube
Copyright © 2026 abinScience. All Rights Reserved. All Products are for Research Use Only